Rib-X Pharmaceuticals, Inc. has raised $50 million in Series C financing round, bringing the total amount raised by the company since 2001 to $123 million.
Rib-X is a biopharma company focusing on small molecule drug discovery and development, particularly on the development of new classes of antibiotics targting the 50s ribosome.
In addition to Warburg Pincus, investors participating include:
- ABS Ventures
- Axiom Venture Partners
- Cardinal Partners
- Euclid SR Partners
- Oxford Bioscience Partners
- S.R. One, Limited
- MedImmune Ventures, Inc.
- Radius Ventures
Comment Preview